Kornimate/medical-research-clean huggingface dataset:
dermacyd silver floral (lactic acid) - compatibility - stay on floral

Conditions: Hygiene

Summary: primary objective: to demonstrate the absence of irritation potential (primary dermic irritability and cumulated dermic irritability) and allergy (sensibilization) of the product dermacyd phdesilstyfl.


Eligibility criteria:
inclusion criteria: * phototype skin i,ii, iii e iv integral skin test in the region * willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion; exclusion criteria: * lactation or pregnancy * use of antiinflammatory 30 days and/or immunossupression drugs for until 3 months before volunteers selection * disease which can cause immunosuppresion, such as diabetes, hiv * use of antihistamines 30 days before selection * personnel history of atopy * history of sensitivity or irritation for topic products * cutaneous active disease (local and/or general) which can modify the study results * use of new drugs and/or cosmetics during the study * cutaneous reactive * previous participation in studies using the same product in test * volunteer which has immunodeficiency congenital or acquired * relevant history or confirmation of alcohol or other drugs abuse * intolerance detected or suspected for some component of the sample tested * medecin or sponsor employees or their close family the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
radiation therapy using helical tomotherapy imrt for head and neck cancer

Conditions: Cancer

Summary: historically, patients with stage iii and iv head and neck cancer have been treated with surgery and/or radiation therapy. based on the results of recent clinical trials, in patients not able to undergo surgery, chemotherapy with radiation therapy has been adopted as the current standard of care. the chemo-radiation approach, however, entails a significant increase in treatment-related toxicity, limiting the extent to which this treatment can be offered to patients. in this trial, the ability of a new form of radiation therapy delivery called imrt will be evaluated for its ability to reduce the amount of radiation-induced toxicity.

the mechanisms of action to explain the radiation-induced toxic effects resulting from the more aggressive radiation therapy treatments of head and neck cancer include the additive and synergistic increase in mucositis from the combination of chemotherapy and radiotherapy. the severe toxicity associated with more aggressive radiation therapy treatments for locoregional head and neck cancer limits the extent to which these treatments can be offered since many patients present with nutritional deficiencies and consequent general debility. intensity modulated radiotherapy (imrt) is a technology has the potential for exquisite dose painting and structuring in such a manner that it can permit exclusion of normal tissues and sensitive structures from the high dose radiation volume without compromising primary tumor or nodal target coverage. in this phase i/ii feasibility trial, radical radiotherapy will be delivered using helical tomotherapy intensity modulated radiotherapy (ht-imrt) to a dose of 66-70 gy to involved areas and to at least 50 gy to un-involved sites, treated prophylactically. it is hypothesized that the pattern of failure and toxicity profiles of patients treated with helical tomotherapy will demonstrate the greater efficacy of helical tomotherapy, as compared with conventional radiotherapy, in the treatment of cancers of the head and neck.

Eligibility criteria:
inclusion criteria: 1. stage ii, iii or iv non-metastatic histologically confirmed carcinoma of the head and neck region (oral cavity, pharynx or larynx). 2. treatment with radical radiotherapy with or without chemotherapy 3. patients in whom definitive radiotherapy with or without planned neck dissection is the selected curative treatment 4. ecog performance status of 0, 1 or 2 exclusion criteria: 1. previous radiotherapy to head and neck mucosa 2. patients with disabling co-morbid conditions, which do not permit effective immobilization 3. patients with severe trismus, which disallow effective assessment 4. patients in whom it is deemed necessary to commence enteric nutrition prior to the start of treatment.

Keywords: head, neck, cancer, tomotherapy, imrt,
mouvsco: kinematic analysis of the trunk in patients with moderate scoliosis

Conditions: Scoliosis

Summary: the hypothesis of this study is that moderate scoliosis patients have postural and kinematic differences (static and dynamic) compared with healthy volunteers and it is possible to characterize and quantify. the aim of this study is the detailed analysis of postural anomalies in moderate scoliosis patients compared with healthy volunteers

subjects participating in the study must wear sensors that will be arrange at the shoulders, spine, pelvis and legs. subjects will perform under the direction of the investigator, different tasks of a total duration of 45 minutes. during the period of experimentation, the data collected will be: * the positions of each one of the sensors in all three planes of space, * the ground support forces

Eligibility criteria:
scoliosis group - inclusion criteria: * female children patients from 9 to 16 years old, * patients with idiopathic scoliosis lumbar left and / or right thoracic, * patients with moderate scoliosis: cobb angle measured on a radiograph between 10 ° and 25°, * both parents of patients must be affiliated to social security or similarly regime. healthy volunteers group - inclusion criteria: * female children from 9 to 16 years old, matched in age and size with scoliosis patients, * children with no neuromuscular disease that may have an influence on the required tasks, * both parents of children must be affiliated to social security or similarly regime, exclusion criteria: * refusal to consent: from child's in age to consent or from both parents
effect of specific diet and physical activity on weight and/or fat loss

Conditions: Obesity

Summary: the main purpose of this study is to assess metabolic effects (decreased amount of body fat content, insulin sensitivity and lipid profile improvement) of weight loss intervention based on specific life style counseling (low calorie "metabolic stairs" diet and circuit-based exercise in a comparison to conventional diet and exercise. the main hypothesis is that more significant beneficial metabolic effects will have specific life style counseling effect than conventional diet and exercise. the main purpose of this study is to assess above mentioned metabolic changes before and after 6-8 weeks of weight loss intervention. the investigators will also study the following: 1. the impact of life style counseling induced weight and/or fat loss on physical fitness 2. the impact of life style counseling induced weight and/or fat loss on metabolic parameters (e.g. insulin sensitivity, lipid profile, ect.)

i

Eligibility criteria:
inclusion criteria: * healthy volunteers * bmi≥25 kg/m2 exclusion criteria: * thyroid disease * chronic diseases(rheumatic,liver, kidney, pulmonary, etc. diseases) have current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease, or diabetes; * chronic infections * show evidence of malignancy * be women who are pregnant, nursing * medical treatment except allergy medicines * tobacco, alcohol or drug addiction

Keywords: overweight and obesity adipose tissue weight loss program low-calorie diet circuit-based exercise metabolic cardiovascular syndrome
identification of microcirculation after surgical treatment of rupture of the achilles tendon

Conditions: Microcirculation; Achilles Tendon Rupture

Summary: this project investigates microcirculation in skin and tendon after a rupture of the achilles tendon. three different treatments are compared: stitches of the tendon, fibrin-glue and the combination of both.

this project investigates microcirculation in skin and tendon after a rupture of the achilles tendon. three different treatments are compared: stitches of the tendon, fibrin-glue and the combination of both. every method is long established and can be treated as clinical equal. so the surgical treatment is chosen randomly for each patient. for this cause the microcirculation is registered by o2c, which works with measuring reflected lightwaves. it is strictly noninvasive and causes absolutely no pain for the patient. the measurement device consists of two small probes, which simply stick to the patient´s skin. there are nine measurements on this study: one before and one shortly after the surgery, followed by three measuring appointment every 6 hours (6,12,18,24 h post-op).afterwards there are appointments planed after 12 days and 6 month. on the last appointment the patients are questioned according to established scores like aofas or vas to register the functional outcome and level of pain. clinical parameters like time between rupture and surgical treatment, hospitalisation time, and form of anaesthesia are included to create comparable patient profiles. after 6 moths the last measurement appointment is stated, in which the clinical outcome is registered by scores, e.g mann-whitney-wilcoxon-test. this study is to detect any difference in wound heeling, re-rupture rate and functionality between these three methods.

Eligibility criteria:
inclusion criteria: * acute rupture of the achilles tendon (on one or both sides) * older than 18 year of age * firmed letter of approval * patient speaks/understands german * planed surgical treatment * no more than 48h after rupture exclusion criteria: * no-traumatic rupture of the achilles tendon * more than 48h after rupture * no planed surgical treatment * history of surgery on the injured leg * condition of diabetes mellitus * condition of peripheral artery occlusive disease

Keywords: functional outcome
efficacy of winterized pistacia lentiscus oil in reducing purulent bacterial overinfection of pediatric rhinitis

Conditions: Rhinitis Acute

Summary: this study aims to evaluate the efficacy and safety of a medical device containing winterized pistacia lentiscus oil in reducing symptoms of purulent bacterial overinfection in pediatric rhinitis and the need for antibiotic therapy. the randomized controlled trial will compare the treatment group receiving nasal drops with a control group using saline solution.

this is a prospective, multicenter, randomized controlled trial to assess the therapeutic potential of winterized pistacia lentiscus oil (wlo) in pediatric patients aged 2 to 10 years with purulent rhinitis. the study will investigate the reduction of rhinitis symptoms, the need for antibiotics, and secondary outcomes including nasal decongestant activity and treatment safety. participants will be randomized into two groups: the intervention group will receive 3 drops of wlo per nostril, three times daily for six days, while the control group will use 0.9% saline solution under the same regimen. clinical evaluations will be conducted by medical staff and parents over six days to record symptom improvement, antibiotic use, and adverse events. the results will contribute to understanding the potential of wlo as a non-antibiotic treatment option for purulent bacterial overinfection in pediatric rhinitis.

Eligibility criteria:
inclusion criteria: * children aged 2 to 10 years. * clinical symptoms of dense mucosal rhinitis/purulent mucus. * onset of symptoms ≤ 5 days before enrollment. exclusion criteria: * onset of symptoms \> 5 days before enrollment. * presence of neurological, malformative, or immunological pathology. * suspected or confirmed allergy to the active substance. * use of antibiotics within 48 hours prior to enrollment.
database study to provide information on pregnancy and infant outcomes among women exposed to quviviq (daridorexant)

Conditions: Insomnia Disorder

Summary: healthcare claims database study to provide safety information on maternal, fetal and infant outcomes among women exposed to quviviq (daridorexant) during pregnancy

this is a longitudinal observational cohort study using an electronic database of healthcare claims data. safety information will be retrospectively collected from the database and pre-specified diagnostic codes will be used to identify pregnancy and infant outcomes. the study will include two phases, a patient accrual phase (phase 1) and an analysis phase (phase 2). descriptive statistics will be conducted to characterize the patient population and to support the interpretation of comparative analyses. comparative analyses will be performed to estimate the effect of quviviq exposure during pregnancy on the study outcomes. approximately 419 mother-infant pairs with exposure to quviviq and 1676 mother-infant pairs with exposure to non-orexin receptor antagonist insomnia medication are expected with a 1:4 ratio of exposed:active comparator patients. analysis of the prevalence of each specific pregnancy or infant outcome will comprise: (1) a comparison between women with insomnia exposed to quviviq during or shortly prior to pregnancy (quviviq-exposed group) and women with insomnia exposed to any non-orexin receptor antagonist insomnia medication during or shortly prior to pregnancy (active comparator group); (2) a comparison between women with insomnia exposed to quviviq during or shortly prior to pregnancy (quviviq-exposed group) and women with insomnia unexposed to any insomnia medication during or shortly prior to pregnancy (unexposed comparator group).

Eligibility criteria:
1. evidence of a singleton end of pregnancy event during the intake period. 2. ≥ 1 insomnia diagnosis during the period which begins 12 months prior to the date of conception and ends at the end of pregnancy. 3. date of conception ≥ 42 weeks before the end of the intake period. 4. age 15 to 50 years at the date of conception. 5. continuous medical and pharmacy insurance coverage during the period which begins 6 months prior to the date of conception and ends at the end of pregnancy. 6. no dispensing of known or suspected teratogenic medications during the period which begins 5 half lives of that medication prior to the date of conception and ends at the end of pregnancy. 7. no exposure to other orexin receptor antagonists during the exposure period, i.e., suvorexant, lemborexant, and any orexin receptor antagonists newly approved during the intake period.

Keywords: pregnancy
68ga-nota-rm26 pet/ct for the detection of gastrointestinal stromal tumor

Conditions: Gastrointestinal Stromal Tumors

Summary: this is an open-label positron emission tomography/computed tomography (pet/ct) study to investigate the diagnostic performance and evaluation efficacy of 68ga-nota-rm26 in gastrointestinal stromal tumor（gist）patients. a single dose of 55.5 to 148 mbq(1.5-4 mci) of 68ga-nota-rm26 will be injected intravenously. patients underwent whole-body pet/ct scans at 30-90 minutes after intravenous injection.

rm26 is a bioactive polypeptide containing 9 amino acid residues, which can specifically bind to gastrin releasing peptide receptor (grpr, bb2 receptor). previous studies have confirmed that there are a large number of grpr receptors in human common types of tumors, such as lung cancer, breast cancer, prostate cancer, head and neck squamous cell carcinoma, glioma and gastrointestinal tumors. therefore, the use of various radionuclide labeled gastrin releasing peptide receptor analogues rm26 for tumor targeted imaging and treatment greatly improves the early detection rate of tumor, and has important clinical significance and value in tumor staging, prognosis evaluation and curative effect evaluation.this prospective pilot study investigated the use of 68ga-nota-rm26, an antagonist targeting gastrin-releasing peptide receptor (grpr), for evaluating breast cancer using positron-emission tomography/computed tomography (pet/ct).

Eligibility criteria:
inclusion criteria: * patients in suspicion of gastrointestinal stromal tumors by ct or ultrasonography,and being able to provide basic information and sign the written informed consent form. exclusion criteria: * the exclusion criteria included claustrophobia, pregnancy, breastfeeding, kidney or liver failure, inability to fulfill the study, and undergoing any preceding local or systemic therapies that might interfere with grpr binding.

Keywords: pet/ct rm26 grpr gastrin-releasing peptide receptor
a clinical trial evaluating the efficacy of resultz lice and egg elimination kit on pediatric and adult subjects

Conditions: Pediculus Capitis

Summary: a one day study to demonstrate that resultz lice and egg elimination kit is statistically superior to a sham control with one hour of combing.

resultz lice and egg elimination kit will be efficacious in the removal of human head lice infestations in children and adult subjects under simulated real world conditions.

Eligibility criteria:
inclusion criteria: * must have active head lice infestations (at least 1 live louse and eggs) * good general health based on medical history * each subject has to be consented exclusion criteria: * subjects with any condition that would compromise the study * history of irritation or sensitivity to pediculicides or hair care products * subjects with cranial or facial implants * subjects who have received radiation within the last 6 months * subjects with history of heart disease * subjects with history of epilepsy or seizure disorders * subjects with neuro-stimulator or pacemaker * subject with hair that staff cannot comb * subject previously treated in study in last 30 days * use of lice treatment in past 2 weeks * subject unable to sense pain * subject unable to communicate pain

Keywords: lice comb human head lice infestations combing solution
cardiorenal protective diet

Conditions: Chronic Kidney Diseases; Cardiovascular Diseases; Hypertension

Summary: this study will evaluate providing fruits and vegetables in a sustainable community care clinic setting, in addition to routine medical care, to individuals with ckd (stage 2-4) on ckd and cvd risk, or cardio-renal risk factors. further, metabolomics profiling will be used to study how change in the diet affects disease risk. data from this study will be published in peer-reviewed journals, presented at national conferences, and will serve as pilot data to guide and strengthen applications for nih funding.


Eligibility criteria:
inclusion criteria: * willingness to participate in a 3-month f\&v study. * positive urine dipstick (proteinuria and/or albumin-to-creatinine ratio \>=10). * african-american (self-declared) race * a current diagnosis of hypertension or a current blood pressure reading consistent with hypertension (sbp \>= 140 and/or dbp \>=90). * access to the internet via personal computer or mobile device. * ability to read and write in english. exclusion criteria: * negative urine dipstick. * currently receiving dialysis or needing dialysis (stage 5 kidney disease) * have received or need a kidney transplant. * pregnant or planning to become pregnant in the next 6 months. * baseline urine potassium \> 60meq/g creatinine * negative diagnosis of hypertension or blood pressure reading (sbp \<140 or dbp \<90). * nephrotic proteinuria demonstrated on urine acr measurement. * lacking access to the internet via personal computer or mobile device. * unable to read or write in english.

Keywords: cvd dietary intervention
studying the effect of freeze-dried table grape powder on blood estrogen levels in postmenopausal women

Conditions: Breast Cancer

Summary: rationale: estrogen can cause the growth of breast cancer cells. studying samples of blood and urine in the laboratory from participants receiving freeze-dried table grape powder may help doctors understand the effect of this drug on blood estrogen levels. purpose: this clinical trial is studying the effect of freeze-dried table grape powder on blood estrogen levels in postmenopausal women.

objectives: * to measure the change in levels of plasma estrone (e1), estradiol, e1-conjugates, and e1-sulfates in postmenopausal women after 6 weeks of daily ingestion of 94 grams of freeze-dried table grape powder. * to conduct bioavailability research on the freeze-dried table grape powder in humans through the analysis of participants' blood and urine samples. outline: participants receive oral freeze-dried table grape powder once daily on days 1-42 in addition to their usual diet. treatment continues in the absence of toxicity. participants undergo blood sample collection at baseline, periodically after the first dose, and on the last day of the study for pharmacokinetic and bioavailability analysis. samples are examined by mass spectrometry to measure plasma levels of estrone (e1), estradiol, e1-conjugates, e1-sulfates, testosterone, and androstenedione. participants also undergo spot urine collection and weight and height measurement periodically during study. participants complete food diaries on days 1-3, 21-23, and 40-42 to assess their intake of grapes, grape juice, and red wine and to examine the constancy of their caloric intake over the course of the study.

Eligibility criteria:
disease characteristics: * participant in the mayo mammography health study * has consented to provide baseline mammogram for digitization patient characteristics: * ecog performance status 0-1 * female * postmenopausal (defined as women who have had both ovaries removed or no menstrual period for at least 12 consecutive months) * able to give informed consent and complete food records alone or with assistance * willing to provide research blood and urine samples * must be a non-smoker * willing to maintain current weight * no history of breast ductal carcinoma in situ or any other cancer, except basal cell or squamous cell skin cancer or lobular carcinoma in situ * no history of allergic or other adverse reaction to grapes * no history of diabetes or glucose intolerance prior concurrent therapy: * no concurrent hormone therapy, including estradiol, estrone, or progestins

Keywords: breast cancer
a comparison of metacarpophalangeal joint blocking splint with relative motion extension splint for trigger finger

Conditions: Trigger Finger

Summary: the purpose of this research is to evaluate the effectiveness of two splint designs in conservative management of trigger finger.

this study aims to analyse and compare the effectiveness of metacarpophalangeal joint blocking splint versus relative motion extension splint for trigger finger. this will help us find out which one of the two splint designs is more effective in the management of trigger finger, thus improving treatment outcomes for patients with trigger finger.

Eligibility criteria:
inclusion criteria: * trigger finger patient exclusion criteria: * diabetes, non-english speaking